| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1013582348 |
| P356 | DOI | 10.2165/00003088-199325010-00003 |
| P698 | PubMed publication ID | 8354016 |
| P2093 | author name string | Shionoiri H | |
| P2860 | cites work | Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning | Q24293181 |
| Digoxin, Converting-Enzyme Inhibition (Quinapril), and the Combination in Patients with Congestive Heart Failure Functional Class II and Sinus Rhythm | Q28323454 | ||
| A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure | Q28328342 | ||
| Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine | Q28335574 | ||
| Impact of captopril on hemodynamic and hormonal effects of nitroprusside | Q28336353 | ||
| Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients | Q28340055 | ||
| Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy | Q28361081 | ||
| Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases | Q34172660 | ||
| Antihypertensive effects of nitrendipine and cilazapril alone, and in combination in hypertensive patients with chronic renal failure | Q34397144 | ||
| Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients | Q34397173 | ||
| The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors | Q34397541 | ||
| Enalapril in essential hypertension: the comparative effects of additional placebo, nicardipine and chlorthalidone | Q34417431 | ||
| The effect of captopril on the reflex control heart rate: possible mechanisms | Q34446559 | ||
| Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy | Q34626316 | ||
| Lack of effect of captopril on serum digoxin in congestive heart failure | Q34673781 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| Impairment of captopril bioavailability by concomitant food and antacid intake | Q34709053 | ||
| Renal handling of captopril: effect of probenecid | Q34714710 | ||
| Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents | Q34936463 | ||
| Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulant agent | Q35334829 | ||
| Clinical Pharmacokinetics of β-Adrenoreceptor Blocking Drugs | Q35373296 | ||
| Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy | Q35722584 | ||
| The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist | Q36097390 | ||
| Clinical Pharmacology of Cilazapril | Q36661464 | ||
| Captopril in heart failure. A double blind controlled trial | Q36753945 | ||
| Metabolic effects of ACE inhibitors. | Q37739940 | ||
| Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension | Q37931836 | ||
| ACE inhibitors in mild heart failure: first-line or second-line therapy? | Q37936799 | ||
| Comparison of the Steady-State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Patients with Chronic Renal Insufficiency | Q44917912 | ||
| Pharmacokinetics and acute effect on the renin-angiotensin system of delapril in patients with chronic renal failure. | Q45003742 | ||
| Sulindac and cough induced by converting enzyme inhibitors | Q45019140 | ||
| A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction | Q45327798 | ||
| Blood concentration and urinary excretion of enalapril in patients with chronic renal failure. | Q45935716 | ||
| Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients. | Q51613484 | ||
| Glucose and Lipid Metabolism During Long-Term Treatment with Cilazapril in Hypertensive Patients With or Without Impaired Glucose Metabolism | Q51615813 | ||
| Long-term captopril therapy with no effect on glucose metabolism in patients with essential hypertension. | Q51625167 | ||
| Glucose tolerance during chronic captopril therapy in patients with essential hypertension. | Q51630749 | ||
| Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. | Q51640373 | ||
| Enalapril and SPPS. | Q51724260 | ||
| Interaction between enalapril and propofol. | Q51747205 | ||
| Presynaptic angiotensin II receptors and captopril-induced adrenergic transmission failure probably not via converting enzyme inhibition in guinea-pig pulmonary arteries. | Q53877083 | ||
| Antianginal, hemodynamic and coronary vascular effects of captopril in stable angina pectoris | Q54319505 | ||
| Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. | Q54389927 | ||
| Converting-enzyme inhibition and coronary blood flow. | Q54417197 | ||
| Captopril and nifedipine in combination for moderate to severe essential hypertension. | Q54705299 | ||
| Possible interaction between SPPS and enalapril | Q38078349 | ||
| Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects | Q38205193 | ||
| Reperfusion injury and its pharmacologic modification | Q38365078 | ||
| The effects of angiotensin-converting enzyme inhibition on coronary blood flow and infarct size limitation. | Q38690152 | ||
| The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure | Q38713401 | ||
| ACE inhibitors and anaesthesia | Q38751881 | ||
| How to treat hypertension in diabetic patients | Q39466123 | ||
| Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review | Q39496475 | ||
| Enalapril: a review of human pharmacology. | Q39496527 | ||
| Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure | Q39501948 | ||
| Angiotensin I converting enzyme inhibitors and the renal excretion of urate | Q39612692 | ||
| Circulating versus local renin-angiotensin system in cardiovascular homeostasis. | Q39641716 | ||
| Cimetidine-drug interactions | Q40092766 | ||
| Worsening of anemia induced by long-term use of captopril in hemodialysis patients | Q40831010 | ||
| Difference in mortality between patients treated with captopril or enalapril in the xamoterol in severe heart failure study | Q41149104 | ||
| Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope | Q41264230 | ||
| Enhanced sympathetic nervous activity after intravenous propranolol in ischaemic heart disease: plasma noradrenaline splanchnic blood flow and mixed venous oxygen saturation at rest and during exercise | Q41403872 | ||
| A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension | Q41780967 | ||
| Effects on autonomic function of a new angiotensin converting enzyme inhibitor, ramipril | Q41883472 | ||
| Sodium and water excretion in nephrotic patients: effects of changes in renal haemodynamics | Q41901970 | ||
| Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex | Q41910633 | ||
| Absence of a pharmacokinetic interaction between enalapril and frusemide | Q42129553 | ||
| Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients | Q42191385 | ||
| Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. | Q42191392 | ||
| Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway | Q42201566 | ||
| Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study | Q42212899 | ||
| Severe depersonalization and anxiety associated with indomethacin. | Q42259428 | ||
| Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man. | Q42285056 | ||
| Neurological dysfunction in two patients receiving captopril and cimetidine | Q42592514 | ||
| Captopril kinetics | Q42669849 | ||
| A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects | Q43204863 | ||
| The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril | Q43222328 | ||
| Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine | Q43229020 | ||
| Lisinopril and nifedipine: no acute interaction in normotensives | Q43229083 | ||
| Counter-regulatory effects of combined ACE inhibition and calcium antagonism [letter] | Q43230565 | ||
| Is there any interaction between digoxin and enalapril? | Q43240687 | ||
| Differing dosages of captopril and hydrochlorothiazide in the treatment of hypertension: long-term effects metabolic values and intracellular electrolytes | Q43699806 | ||
| Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers | Q43803291 | ||
| Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans | Q43809560 | ||
| Depressor effects and pharmacokinetics of single and consecutive doses of delapril in hypertensive patients with normal or impaired renal function | Q44020798 | ||
| Cimetidine does not alter free unchanged captopril pharmacokinetics and biological effects in healthy volunteer. | Q44099169 | ||
| Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy | Q44177912 | ||
| Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers | Q44198883 | ||
| Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine | Q44343042 | ||
| ACE inhibitors--a cornerstone of the treatment of heart failure | Q44585380 | ||
| Digoxin pharmacokinetics and spirapril, a new ace inhibitor | Q44611225 | ||
| Dose-ranging study to delineate the additive antihypertensive effect of guanabenz and captopril | Q44663251 | ||
| The effects of captopril on serum digoxin and urinary urea and digoxin clearances in patients with congestive heart failure | Q44836170 | ||
| Pharmacokinetics and Antihypertensive Effects of Lisinopril in Hypertensive Patients with Normal and Impaired Renal Function | Q44846967 | ||
| Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol | Q55062328 | ||
| Fever, myalgia, and arthralgia in a patient on captopril and allopurinol | Q55062331 | ||
| Captopril-Induced Functional Renal Insufficiency in Patients with Bilateral Renal-Artery Stenoses or Renal-Artery Stenosis in a Solitary Kidney | Q56775104 | ||
| Renal haemodynamics and comparative effects of captopril in patients with benign- or malignant-essential hypertension, or with chronic renal failure. | Q64914585 | ||
| Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure | Q64951194 | ||
| A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. | Q64988094 | ||
| Pharmacokinetics and Pharmacodynamics of Benazepril in Hypertensive Patients with Normal and Impaired Renal Function | Q67463687 | ||
| Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group | Q67663743 | ||
| The Effect of Captopril on Pharmacokinetics of Digoxin in Patients with Mild Congestive Heart Failure | Q67692704 | ||
| Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by captopril and reduced thiols | Q67699801 | ||
| Converting Enzyme Inhibitors and the Role of the Sulfhydryl Group in the Potentiation of Exo- and Endogenous Nitrovasodilators | Q67705550 | ||
| Associated Effect of Hepatic Hydroxymethylglutaryl Coenzyme A Reductase + Angiotensin Converting Enzyme Inhibitors on the Progression of Renal Failure in Hypertensive Subjects | Q67771450 | ||
| Left ventricular hypertrophy as a risk factor: the Framingham experience | Q67906792 | ||
| Lisinopril-Induced Lithium Toxicity | Q67914596 | ||
| A 50-year old man undergoing a right thoracotomy experiences unexpected intraoperative hypotension due to a drug interaction | Q67930233 | ||
| Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies | Q68053927 | ||
| Angiotensin II inhibits baroreflex control of muscle sympathetic nerve activity and the heart rate in patients with essential hypertension | Q68058692 | ||
| Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha 1-blocker | Q68086081 | ||
| Glucose metabolism during captopril mono- and combination therapy in diabetic hypertensive patients: a multiclinic trial | Q68170198 | ||
| Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure | Q68194523 | ||
| Multiple-dose cimetidine administration does not influence the single-dose pharmacokinetics of quinapril and its active metabolite (CI-928) | Q68291849 | ||
| A single dose study of the effects of fenoldopam and enalapril in mild hypertension | Q68305945 | ||
| Pentopril-Cimetidine Interaction Caused by a Reduction in Hepatic Blood Flow | Q68329020 | ||
| Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment | Q68456877 | ||
| A case of lisinopril-induced lithium toxicity | Q68486782 | ||
| Lithium and converting enzyme inhibitors | Q68504852 | ||
| A case of acute renal failure induced by the co-administration of NSAIDs and captopril | Q68524282 | ||
| Interaction of captopril and ibuprofen on glomerular and tubular function in humans | Q68534123 | ||
| Topical capsaicin induces cough in patient receiving ACE inhibitor | Q68573989 | ||
| Multiple-dose propranolol administration does not influence the single dose pharmacokinetics of quinapril and its active metabolite (quinaprilat) | Q68758983 | ||
| [The antihypertensive effect and the pharmacokinetic profile of captopril retard (CS-522-R) in patients with essential hypertension] | Q68879236 | ||
| Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension | Q68938377 | ||
| Vascular and aldosterone responses to angiotensin II in normal humans: effects of nicardipine | Q68953297 | ||
| Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group | Q69013550 | ||
| Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function | Q69025121 | ||
| A clinical pharmacological study of nifedipine and lisinopril alone and in combination | Q69030823 | ||
| Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second-step treatment of hypertensive patients not controlled by enalapril alone | Q69061935 | ||
| Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension | Q69152713 | ||
| Volume homeostasis, angiotensin converting enzyme inhibition, and lithium therapy | Q69192807 | ||
| Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol | Q69356122 | ||
| The interaction between indomethacin and captopril or enalapril in healthy volunteers | Q69357217 | ||
| ACE inhibitors in pregnancy | Q69371269 | ||
| Interference of different ACE-inhibitors with the diuretic action of furosemide and hydrochlorothiazide | Q69387602 | ||
| Pharmacokinetics and depressor effect of delapril in patients with essential hypertension | Q69718633 | ||
| 1989 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting | Q69787682 | ||
| An evaluation of the potential interaction between enalapril and amiloride | Q69812044 | ||
| Enalapril and atenolol in essential hypertension: attenuation of hypotensive effects in combination | Q69821628 | ||
| [Diclofenac and cough induced by converting enzyme inhibitors] | Q69834889 | ||
| Pharmacokinetics of lisinopril | Q69837908 | ||
| A possible drug interaction between rifampicin and enalapril | Q69844310 | ||
| Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect | Q69880735 | ||
| Captopril and insulin sensitivity | Q69881306 | ||
| Angiotensin converting enzyme inhibitors and lithium treatment | Q69882461 | ||
| Effect of captopril on heavy proteinuria in azotemic diabetics | Q69919290 | ||
| [Lithium-converting enzyme inhibitors: a combination to avoid?] | Q70048672 | ||
| Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction | Q70056002 | ||
| [Interaction of lithium and angiotensin-converting enzyme inhibitors] | Q70057270 | ||
| Serum concentration and effects of a single dose of enalapril maleate in patients with essential hypertension | Q70078180 | ||
| Effect of captopril on blood pressure and renal function in patients with transplant renal artery stenosis | Q70079813 | ||
| Indomethacin-enalapril interaction: an alert | Q70112082 | ||
| Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension | Q70169574 | ||
| Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor | Q70174360 | ||
| Influence of renal function on the pharmacokinetics of ramipril (HOE 498) | Q70177657 | ||
| Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure | Q70196940 | ||
| Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study | Q70218323 | ||
| Effect of food on the bioavailability of captopril in healthy subjects | Q70226041 | ||
| Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril | Q70230224 | ||
| Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension | Q70239493 | ||
| The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects | Q70244821 | ||
| Nonsteroidal anti-inflammatory drugs and antihypertensives. Cooperative malfeasance | Q70251361 | ||
| A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group | Q70275799 | ||
| Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension | Q70361433 | ||
| The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) | Q70534223 | ||
| Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans | Q70548013 | ||
| Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency | Q70743648 | ||
| [Blood concentration and urinary excretion of captopril (SQ 14,255), angiotensin converting enzyme activity and R-A-A system after administration of captopril--in patients with chronic renal failure compared with essential hypertension] | Q71440616 | ||
| Disposition of captopril in normal subjects | Q72132482 | ||
| Dilation of forearm blood vessels after angiotensin-converting-enzyme inhibition by captopril in hypertensive patients | Q72385837 | ||
| Effects of a cardioselective beta1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction | Q72552257 | ||
| Pre- and postjunctional inhibition of vascular sympathetic function by captopril in SHR. Implication of vascular angiotensin II in hypertension and antihypertensive actions of captopril | Q72641394 | ||
| Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension | Q93527707 | ||
| P433 | issue | 1 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 20-58 | |
| P577 | publication date | 1993-07-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Pharmacokinetic drug interactions with ACE inhibitors | |
| P478 | volume | 25 |
| Q40478996 | ACE Inhibitors Drug Interactions of Clinical Significance |
| Q41175157 | ACE inhibitors and the kidney. A risk-benefit assessment |
| Q40953058 | ACE inhibitors. Differential use in elderly patients with hypertension |
| Q35570981 | Antihypertensive therapy: special focus on drug interactions |
| Q47913024 | Clinical pharmacokinetics of vasodilators. Part I. |
| Q43797278 | Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications |
| Q33211891 | Drug interactions with angiotensin receptor blockers. |
| Q35178549 | Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives |
| Q40511761 | Drug interactions with antacids. Mechanisms and clinical significance |
| Q34347254 | Drug interactions with irbesartan |
| Q33747102 | Effects of food on clinical pharmacokinetics |
| Q35338096 | Epidemiology and management of antiretroviral-associated cardiovascular disease |
| Q41508743 | Fosinopril. Clinical pharmacokinetics and clinical potential |
| Q36648826 | Imidapril in heart failure |
| Q42019856 | In Vitro Evaluation of Inhibitory Effects of Antidiabetic and Antihyperlipidemic Drugs on Human Carboxylesterase Activities |
| Q36717991 | Lack of interaction between ramipril and simvastatin |
| Q57224296 | Lithium ACE inhibitors, NSAIDs, and verapamil. A possible fatal combination |
| Q44261941 | Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability |
| Q41190766 | Optimal dosage of ACE inhibitors in older patients |
| Q34723818 | Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs |
| Q41589500 | Systolic hypertension in the elderly |
| Q86838173 | Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors |
| Q57103311 | Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders |
Search more.